Patents by Inventor Martha B. Ladner

Martha B. Ladner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding N?2 CSF-1 (short form) and carboxy truncated fragment thereof
    Patent number: 6204020
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both “long” and “short” forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: March 20, 2001
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments thereof
    Patent number: 6156300
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: December 5, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding NV2 (long form) and carboxy truncated fragments thereof
    Patent number: 6146851
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: November 14, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof
    Patent number: 6117422
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 12, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2 CSF-1 (short form) and carboxy truncated fragments thereof
    Patent number: 6103224
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 15, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding N- and C- terminally truncated colony stimulating factor-1 variants
    Patent number: 5681719
    Abstract: DNA for new forms of CSF-1 are provided which relate to N-terminal and C-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short and long forms of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 149.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: October 28, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N- 3 deletion mutants of the long form of CSF-1
    Patent number: 5672343
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the long form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 30, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N-.gradient.3 deletion mutants of the short form of CSF-1
    Patent number: 5643563
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: July 1, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding various forms of colony stimulating factor-1
    Patent number: 5573930
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: December 28, 1992
    Date of Patent: November 12, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Recombinant colony stimulating factor-1
    Patent number: 5470569
    Abstract: A colony stimulating factor. CSF-1, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: November 28, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Ernest S. Kawasaki, Martha B. Ladner, Janelle N. Van Arsdell, Alice M. Wang, Peter Ralph, Mazie Y. Coyne, Mary K. Warren
  • DNA encoding for CSF-1 and accompanying recombinant systems
    Patent number: 4847201
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: February 9, 1988
    Date of Patent: July 11, 1989
    Assignee: Cetus Corporation
    Inventors: Ernest S. Kaswasaki, Martha B. Ladner, Janelle N. Van Arsdell, Alice M. Wang, Peter Ralph, Mazie Y. Coyne, Mary K. Warren
  • Human tumor necrosis factor
    Patent number: 4677064
    Abstract: Human Tumor necrosis factor (TNF) has been prepared using recombinant methods. A human promyelocytic leukemia cell line has been induced using an improved induction procedure, and the TNF purified to homogeneity. Methods, vectors, and cells useful in obtaining human TNF in practical amounts are disclosed. Muteins having N-terminal deletions, which muteins have superior biological activity, are also disclosed.
    Type: Grant
    Filed: May 2, 1985
    Date of Patent: June 30, 1987
    Assignee: Cetus Corporation
    Inventors: David F. Mark, Alice M. Wang, Martha B. Ladner, Abla A. Creasey, Janelle N. Van Arsdell, Leo S. Lin
  • Human tumor necrosis factor
    Patent number: 4677063
    Abstract: Human tumor necrosis factor (TNF) has been prepared using recombinant methods. A human promyelocytic leukemia cell line has been induced using an improved induction procedure, and the TNF purified to homogeneity. Methods, vectors, and cells useful in obtaining human TNF in practical amounts are disclosed. Muteins having N-terminal deletions, which muteins have superior biological activity, are also disclosed.
    Type: Grant
    Filed: July 30, 1985
    Date of Patent: June 30, 1987
    Assignee: Cetus Corporation
    Inventors: David F. Mark, Alice M. Wang, Martha B. Ladner, Abla A. Creasey, Leo S. Lin, Janelle Van Arsdell